Phase 2 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Reltecimod (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms REAKT
- Sponsors Atox Bio
- 30 Oct 2018 Planned End Date changed from 1 Sep 2019 to 1 Mar 2020.
- 30 Oct 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated